Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapyCheng Liao, Seng‐Lai Tan|Arthritis Research & Therapy|2013Cited by 46